Aurobindo Pharma Ltd AI Stock Analysis
Want to see IN:AUROPHARMA full AI Analyst Report?
Aurobindo Pharma Ltd (AUROPHARMA) AI Stock Analysis
Aurobindo Pharma Ltd
(NSE:AUROPHARMA)
The score is primarily supported by solid financial health (steady growth, conservative leverage, and a strong 2026 free-cash-flow rebound) and constructive technicals (price above key moving averages with positive MACD). This is tempered by weaker valuation support (higher P/E and low dividend yield) and some fundamental watch items such as 2026 margin compression and moderate ROE.
Aurobindo Pharma Ltd (AUROPHARMA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.04T
- Dividend Yield
- 0.39%
- Average Volume (3M)
- 52.24K
- Price to Earnings (P/E)
- 26.1
- Beta (1Y)
- 0.63
- Revenue Growth
- 13.53%
- EPS Growth
- 17.04%
- Country
- India
- Employees
- 29,209
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Aurobindo Pharma Ltd Business Overview & Revenue Model
Company Description
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquid...
Aurobindo Pharma Ltd Financial Statement Overview
Summary
Overall fundamentals are sound: steady revenue growth and solid EBITDA/net margins, a conservatively levered balance sheet with improving debt-to-equity, and a sharp rebound to strong positive free cash flow in 2026. Offsetting this, 2026 margin compression (notably lower gross margin), relatively flat net income across 2024–2026, and only moderate ROE suggest profitability quality needs monitoring.
Income Statement
72PositiveBalance Sheet
78PositiveCash Flow
70Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 368.68B | 336.53B | 317.24B | 290.02B | 248.55B | 234.55B |
| Gross Profit | 165.31B | 131.96B | 182.40B | 160.16B | 132.14B | 130.06B |
| EBITDA | 80.22B | 72.74B | 65.78B | 58.83B | 37.56B | 44.33B |
| Net Income | 39.90B | 35.05B | 34.86B | 31.73B | 19.27B | 26.48B |
Balance Sheet | ||||||
| Total Assets | 617.54B | 585.02B | 497.85B | 450.72B | 398.90B | 339.22B |
| Cash, Cash Equivalents and Short-Term Investments | 99.78B | 106.18B | 82.36B | 63.25B | 62.24B | 45.58B |
| Total Debt | 86.30B | 80.73B | 82.63B | 66.48B | 52.86B | 32.79B |
| Total Liabilities | 223.56B | 206.19B | 171.38B | 152.21B | 130.38B | 93.48B |
| Stockholders Equity | 394.00B | 378.91B | 326.53B | 298.43B | 268.40B | 245.76B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 28.27B | 19.57B | -11.27B | -3.34B | 23.12B |
| Operating Cash Flow | 0 | 55.13B | 39.25B | 24.35B | 23.87B | 50.16B |
| Investing Cash Flow | 0 | -37.89B | -18.76B | -42.56B | -39.78B | -32.12B |
| Financing Cash Flow | 0 | -9.25B | 1.20B | 8.00B | 18.14B | -29.69B |
Aurobindo Pharma Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Positive. The current price of 1795.30 is above the 20-day moving average (MA) of 1723.82, above the 50-day MA of 1693.01, and above the 200-day MA of 1491.92, indicating a bullish trend. The MACD of 42.12 indicates Negative momentum. The RSI at 62.49 is Neutral, neither overbought nor oversold. The STOCH value of 56.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AUROPHARMA.
Aurobindo Pharma Ltd Peers Comparison
Overall Rating
IN:AUROPHARMA69Neutral
IN:TORNTPHARM69Neutral
IN:LUPIN67Neutral
IN:SUNPHARMA64Neutral
IN:DRREDDY62Neutral
IN:ZYDUSLIFE61Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | INR 1.04T | 26.09 | ― | 0.39% | 13.53% | 17.04% | |
| 69Neutral | INR 1.76T | 76.83 | ― | 0.32% | 42.06% | -3.48% | |
| 67Neutral | INR 914.13B | 17.68 | ― | 0.90% | 24.22% | 20.24% | |
| 64Neutral | INR 4.57T | 41.24 | ― | 0.85% | 12.13% | 4.94% | |
| 62Neutral | INR 1.17T | 41.38 | ― | 0.58% | -3.60% | -52.23% | |
| 61Neutral | INR 1.20T | 28.82 | ― | 0.08% | 24.02% | -14.86% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:AUROPHARMA | Aurobindo Pharma Ltd | 1795.30 | 605.52 | 50.89% | |
| IN:DRREDDY | Dr. Reddy's Laboratories Ltd. | 1390.50 | 173.47 | 14.25% | |
| IN:LUPIN | Lupin Limited | 2010.00 | 25.69 | 1.29% | |
| IN:SUNPHARMA | Sun Pharmaceutical Industries Limited | 1885.10 | 120.02 | 6.80% | |
| IN:TORNTPHARM | Torrent Pharmaceuticals Ltd | 4698.80 | 1013.24 | 27.49% | |
| IN:ZYDUSLIFE | Zydus Lifesciences Limited | 1195.05 | 269.28 | 29.09% |
Aurobindo Pharma Ltd Corporate Events
Aurobindo Pharma Submits Q2 FY27 Earnings Call Transcript
Aurobindo Pharma Limited is a pharmaceutical company with disclosed business areas including biosimilars, vaccines, peptides, specialties and formulations for the U.S. and Europe. It submitted the transcript of its Q2 FY27 earnings call to the NSE an...
Aurobindo Pharma to Participate in JM Financial Investor Conference
Aurobindo Pharma Limited is a pharmaceutical company focused on generic medicines and active pharmaceutical ingredients, serving domestic and international markets.Company officials will participate in JM Financial’s India Xchange 2026 Annual India C...
Aurobindo Pharma expands into U.S. contract research with A1 Biochem acquisition
Aurobindo Pharma, via its wholly owned subsidiary Apitoria Pharma Private Limited, is advancing its strategy to build a contract research footprint by acquiring the Contract Research Services business of A1 Biochem Group. This extends the company’s r...
Aurobindo Pharma Wins USFDA Nod for First Inhaler, Targeting $301 Million Asthma Market
Aurobindo Pharma has received final approval from the US Food & Drug Administration to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths, the generic equivalent of Teva’s QVAR inhalation aerosol....
Aurobindo Pharma Injects $1 Million into New U.S. R&D Arm After A1 Biochem Deal
Aurobindo Pharma has taken another step in its acquisition of the A1 Biochem Group by funding a newly formed U.S. subsidiary, A1 Biochem USA Inc, through its step-down subsidiary A1 Biochem Labs (India) Private Limited. The Indian unit has subscribed...
Aurobindo Pharma to Join ICICI Securities Investor Meeting on September 17
Aurobindo Pharma has informed the stock exchanges that its officials will participate in an investor and analyst group meeting organized by ICICI Securities in Hyderabad on September 17, 2026, between 2:30 PM and 3:30 PM IST. The company emphasized t...
Aurobindo Pharma to Engage Investors at Kotak Healthcare Forum 2026
Aurobindo Pharma Limited has notified the stock exchanges that its officials will participate in the Kotak Healthcare Forum 2026 in Mumbai on September 18, 2026, with one-on-one and group meetings scheduled throughout the day. The company clarified t...
Aurobindo Pharma’s Lannett Unit Completes Routine U.S. FDA Inspection With Procedural Observations
Aurobindo Pharma has reported the completion of a routine U.S. FDA inspection at Lannett Company LLC, its wholly owned step-down subsidiary in Seymour, Indiana. The inspection, conducted from August 17 to 21, 2026, resulted in four procedural observa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 23, 2026
